Revvity (NYSE:RVTY) Price Target Cut to $127.00 by Analysts at Robert W. Baird

Revvity (NYSE:RVTY - Get Free Report) had its price objective dropped by research analysts at Robert W. Baird from $141.00 to $127.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price objective would indicate a potential upside of 33.40% from the stock's previous close.

Other research analysts also recently issued research reports about the stock. Raymond James restated an "outperform" rating and set a $145.00 price target (up previously from $140.00) on shares of Revvity in a report on Monday, February 3rd. Barclays decreased their price target on Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Sanford C. Bernstein lowered Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price for the company. in a report on Friday, January 10th. KeyCorp lifted their price target on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Wells Fargo & Company lowered their target price on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $130.50.

Revvity Stock Up 1.6 %

RVTY traded up $1.52 on Monday, reaching $95.20. 2,167,978 shares of the company traded hands, compared to its average volume of 910,104. The stock's 50 day moving average price is $105.56 and its 200-day moving average price is $113.47. The company has a market cap of $11.44 billion, a price-to-earnings ratio of 43.08, a PEG ratio of 3.82 and a beta of 1.07. Revvity has a 52-week low of $88.53 and a 52-week high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the previous year, the business earned $1.25 earnings per share. On average, sell-side analysts expect that Revvity will post 4.94 EPS for the current fiscal year.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This represents a 31.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.68% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RVTY. T. Rowe Price Investment Management Inc. raised its position in shares of Revvity by 16.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after acquiring an additional 2,969,326 shares during the last quarter. EdgePoint Investment Group Inc. raised its holdings in Revvity by 51.1% during the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock worth $452,939,000 after purchasing an additional 1,372,456 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Revvity by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock valued at $851,764,000 after purchasing an additional 1,151,821 shares during the period. Norges Bank bought a new position in shares of Revvity in the 4th quarter valued at about $127,801,000. Finally, GAMMA Investing LLC grew its position in shares of Revvity by 15,023.0% during the 1st quarter. GAMMA Investing LLC now owns 287,035 shares of the company's stock worth $30,368,000 after buying an additional 285,137 shares during the period. Institutional investors own 86.65% of the company's stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.